M12 Stock Overview
Provides aesthetic medicine and plastic surgery services in Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, Hungary, Bulgaria, Romania, and Australia.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 4/6 |
Financial Health | 5/6 |
Dividends | 1/6 |
M1 Kliniken AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €16.60 |
52 Week High | €22.40 |
52 Week Low | €8.22 |
Beta | 1.18 |
11 Month Change | 14.48% |
3 Month Change | -22.07% |
1 Year Change | 86.52% |
33 Year Change | 115.58% |
5 Year Change | 50.91% |
Change since IPO | 232.07% |
Recent News & Updates
Recent updates
Why We're Not Concerned Yet About M1 Kliniken AG's (ETR:M12) 27% Share Price Plunge
Aug 03Additional Considerations Required While Assessing M1 Kliniken's (ETR:M12) Strong Earnings
Jun 06M1 Kliniken AG (ETR:M12) Looks Just Right With A 53% Price Jump
May 29M1 Kliniken (ETR:M12) Might Be Having Difficulty Using Its Capital Effectively
May 03At €14.40, Is It Time To Put M1 Kliniken AG (ETR:M12) On Your Watch List?
Mar 07Why Investors Shouldn't Be Surprised By M1 Kliniken AG's (ETR:M12) 25% Share Price Surge
Feb 18Is M1 Kliniken AG (ETR:M12) Trading At A 46% Discount?
Feb 17An Intrinsic Calculation For M1 Kliniken AG (ETR:M12) Suggests It's 27% Undervalued
Sep 01Should You Think About Buying M1 Kliniken AG (ETR:M12) Now?
Jun 01The Returns On Capital At M1 Kliniken (ETR:M12) Don't Inspire Confidence
Mar 25Investors Could Be Concerned With M1 Kliniken's (ETR:M12) Returns On Capital
Dec 17Is Now The Time To Look At Buying M1 Kliniken AG (ETR:M12)?
Nov 02Time To Worry? Analysts Are Downgrading Their M1 Kliniken AG (ETR:M12) Outlook
May 26Analysts Have Lowered Expectations For M1 Kliniken AG (ETR:M12) After Its Latest Results
May 25Here's What's Concerning About M1 Kliniken's (ETR:M12) Returns On Capital
Dec 06There Are Reasons To Feel Uneasy About M1 Kliniken's (ETR:M12) Returns On Capital
May 22Here's What M1 Kliniken AG's (ETR:M12) Shareholder Ownership Structure Looks Like
Mar 19We're Watching These Trends At M1 Kliniken (ETR:M12)
Feb 21M1 Kliniken (ETR:M12) Has Gifted Shareholders With A Fantastic 106% Total Return On Their Investment
Feb 03Are Dividend Investors Getting More Than They Bargained For With M1 Kliniken AG's (ETR:M12) Dividend?
Jan 16M1 Kliniken AG's (ETR:M12) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Dec 29Here's Why We Don't Think M1 Kliniken's (ETR:M12) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 14When Should You Buy M1 Kliniken AG (ETR:M12)?
Nov 28Shareholder Returns
M12 | DE Healthcare | DE Market | |
---|---|---|---|
7D | 16.9% | 0.7% | -3.0% |
1Y | 86.5% | 7.0% | 3.5% |
Return vs Industry: M12 exceeded the German Healthcare industry which returned 7% over the past year.
Return vs Market: M12 exceeded the German Market which returned 3.5% over the past year.
Price Volatility
M12 volatility | |
---|---|
M12 Average Weekly Movement | 8.1% |
Healthcare Industry Average Movement | 3.8% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 11.8% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: M12's share price has been volatile over the past 3 months.
Volatility Over Time: M12's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 219 | Attila Strauss | www.m1-kliniken.de |
M1 Kliniken AG, together with its subsidiaries, provides aesthetic medicine and plastic surgery services in Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, Hungary, Bulgaria, Romania, and Australia. It operates in two segments, Beauty and Trade. The Beauty segment provides aesthetic surgery services, such as breast augmentation, eyelid lifts, and liposuction; and other aesthetic medical treatment services, including injections with hyaluronic acid and botulinum toxin.
M1 Kliniken AG Fundamentals Summary
M12 fundamental statistics | |
---|---|
Market cap | €304.03m |
Earnings (TTM) | €10.27m |
Revenue (TTM) | €316.32m |
29.6x
P/E Ratio1.0x
P/S RatioIs M12 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
M12 income statement (TTM) | |
---|---|
Revenue | €316.32m |
Cost of Revenue | €283.85m |
Gross Profit | €32.47m |
Other Expenses | €22.20m |
Earnings | €10.27m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.56 |
Gross Margin | 10.27% |
Net Profit Margin | 3.25% |
Debt/Equity Ratio | 3.8% |
How did M12 perform over the long term?
See historical performance and comparison